Fulgent Genetics (MEX:FLGT) Equity-to-Asset : 0.92 (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Fulgent Genetics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Fulgent Genetics's Total Stockholders Equity for the quarter that ended in Jun. 2024 was MXN20,748 Mil. Fulgent Genetics's Total Assets for the quarter that ended in Jun. 2024 was MXN22,575 Mil. Therefore, Fulgent Genetics's Equity to Asset Ratio for the quarter that ended in Jun. 2024 was 0.92.

The historical rank and industry rank for Fulgent Genetics's Equity-to-Asset or its related term are showing as below:

MEX:FLGT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.76 Med: 0.91 Max: 0.96
Current: 0.92

During the past 10 years, the highest Equity to Asset Ratio of Fulgent Genetics was 0.96. The lowest was 0.76. And the median was 0.91.

MEX:FLGT's Equity-to-Asset is ranked better than
97.37% of 228 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.6 vs MEX:FLGT: 0.92

Fulgent Genetics Equity-to-Asset Historical Data

The historical data trend for Fulgent Genetics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulgent Genetics Equity-to-Asset Chart

Fulgent Genetics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

Get a 7-Day Free Trial

0.93

0.81

0.91

0.92

Fulgent Genetics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Equity-to-Asset	Get a 7-Day Free Trial															0.93	0.93	0.92	0.92	0.92

Competitive Comparison of Fulgent Genetics's Equity-to-Asset

For the Diagnostics & Research subindustry, Fulgent Genetics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fulgent Genetics's Equity-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Fulgent Genetics's Equity-to-Asset falls into.

Fulgent Genetics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Fulgent Genetics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	19284.46	/	20968.764
	=	0.92

Fulgent Genetics's Equity to Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

Equity to Asset (Q: Jun. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	20748.414	/	22574.745
	=	0.92

Fulgent Genetics (MEX:FLGT) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Fulgent Genetics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Fulgent Genetics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Fulgent Genetics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (MEX:FLGT) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

FLGT:USA 7F0:Germany

Address

4978 Santa Anita Avenue, Temple City, CA, USA, 91780

Website

https://www.fulgentgenetics.com

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.